Sandoz CEO Takes Stock Of Generics Industry After A Year Of Lockdowns
Richard Saynor Identifies Three Key Areas To Watch Going Forward
Sandoz CEO Richard Saynor has spoken of the ways in which the pandemic has changed the industry, from supply chains to working patterns, and makes predictions for the years ahead.
You may also be interested in...
Weaknesses in the global pharmaceutical supply chain, exposed and exacerbated by the coronavirus pandemic, have led major markets to pursue localization policies aimed at bolstering domestic production capacity. But any significant transformation promises to take many years.
Sandoz has struck a deal worth up to $500m for GlaxoSmithKline’s cephalosporin antibiotics business, in a move that the Novartis subsidiary says will reinforce its leadership position in the field.
In this latest installment of VC playbook, In Vivo speaks to Naveed Siddiqi, senior partner at Novo Ventures. He discusses the group’s strategy, the European investment outlook for life sciences and how COVID-19 has permanently shifted perceptions of the biopharma industry.